TA
ABBV icon

TFB Advisors’s AbbVie ABBV Stock Holding History

TFB Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,258
Closed -$287K – 181
2025
Q4 		$287K Sell
1,258
-77
-6% -$17.5K 0.08% 247
2025
Q3 		$306K Sell
1,335
-609
-31% -$124K 0.09% 238
2025
Q2 		$361K Sell
1,944
-232
-11% -$43.1K 0.09% 229
2025
Q1 		$456K Buy
2,176
+378
+21% +$73.5K 0.13% 183
2024
Q4 		$320K Buy
1,798
+15
+0.8% +$2.76K 0.09% 228
2024
Q3 		$352K Buy
1,783
+59
+3% +$11K 0.1% 215
2024
Q2 		$296K Buy
1,724
+108
+7% +$17.9K 0.1% 227
2024
Q1 		$261K Buy
+1,616
New +$279K 0.09% 224
2023
Q4 		– Sell
-2,267
Closed -$338K – 170
2023
Q3 		$338K Buy
2,267
+706
+45% +$104K 0.41% 70
2023
Q2 		$210K Buy
+1,561
New +$229K 0.09% 217

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TFB Advisors's ABBV Position: Q1 2026 in Review

TFB Advisors sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,258 shares — an estimated $287K sold.

TFB Advisors first reported a position in ABBV in Q2 2023 and held it in 10 quarters. The position peaked at $456K in Q1 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TFB Advisors reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • TFB Advisors sold 1,258 AbbVie shares in Q1 2026, an estimated $287K.
  • TFB Advisors first reported a position in AbbVie in Q2 2023 and held it in 10 quarters.
  • TFB Advisors's AbbVie position peaked at $456K in Q1 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TFB Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.